KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations severely limit therapeutic options. The results of a study led by the Center for Cancer Research at the Medical University of Vienna, recently published in the journal EMBO Molecular Medicine, now raise a previously little-considered strategy: the targeted blockade of the EGFR signaling pathway – even in the presence of a KRAS mutation. This could make KRAS-mutated colon cancer more treatable than previously thought.

A new guideline to diagnose and treat hypertension is aimed at helping primary care clinicians, including family physicians, nurses, nurse practitioners, and pharmacists, manage the disease. The new guideline, the first of 2 from Hypertension Canada, is published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241770, and will be republished with permission in Canadian Family Physician and Canadian Pharmacists Journal, with a summary in Canadian Nurse.

A new,  blood-based method of analysing thousands of proteins in a single, untargeted test will greatly help the diagnosis of rare diseases in babies and children, avoiding what is sometimes years of inconclusive investigations and invasive tests.

Daylight can boost the immune system’s ability to fight infections.